Pfizer expects to earn $15bn in 2021 from Covid-19 vaccine
Pfizer is commanding a higher price for its vaccine than some rivals
02 February 2021 - 16:49
Pfizer said it expected about $15bn in revenue in 2021 from the Covid-19 vaccine it developed with BioNTech, a sign of returns to come from the industry’s pandemic response efforts.
The vaccine projection primarily includes doses that are expected to be delivered in 2021 under existing contracts, Pfizer said on Tuesday as it reported fourth-quarter earnings. The forecast may be adjusted in the future as additional contracts are reached...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.